MedinCell S.A. MDCLF
Set alert
At close · Feb 5
- YTD
- +392.69%
- 1 year
- +392.69%
- Open
- 6.99
- Prev close
- 34.39
- Mkt cap
- 1.24B
- Vol
- 21.64K
- Avg vol
- 9
- EPS
- -1.09
- P/E
- 0.00
More statistics
- Low
- 6.98
- High
- 6.98
News
2 weeks ago businesswire.com
Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that it has secured an additional €13.8 million in non-dilutive financing from leading European commercial…
3 weeks ago seekingalpha.com
MedinCell S.A. (MDCLF) Discusses U.S. Approval of Weltruza and Its Impact on Schizophrenia Treatment and Financial Outlook Transcript
MedinCell S.A. (MDCLF) Discusses U.S. Approval of Weltruza and Its Impact on Schizophrenia Treatment and Financial Outlook Transcript
3 weeks ago businesswire.com
Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Medincell will host Investor webcast today to discuss the implications of the approval for the Company and answer…
1 month ago businesswire.com
Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
MONTPELLIER, France--(BUSINESS WIRE)--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's…
1 month ago businesswire.com
Medincell to Participate in Upcoming Investor Conferences
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today…
1 month ago businesswire.com
Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): The Annual General Meeting and Extraordinary General Meeting will be held at Medincell's headquarters (3 rue des Frères…
2 months ago businesswire.com
Medincell Appoints Edna Venneker, MD, as Chief Medical Officer
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext: MEDCL), a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple…
2 months ago businesswire.com
Medincell's Dr Grace Kim to Participate in Piper Sandler CNS Symposium
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable…
3 months ago businesswire.com
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a…
3 months ago businesswire.com
Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director…
3 months ago businesswire.com
Medincell Aligns Debt Maturity with Its Expected Revenue Growth Trajectory
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align…
4 months ago seekingalpha.com
MedinCell S.A. (MDCLF) Q4 2026 Earnings Call Transcript
MedinCell S.A. (MDCLF) Q4 2026 Earnings Call Transcript
4 months ago businesswire.com
Medincell Reports FY 2025-26 Annual Results
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Key Financial Highlights Total revenues €24.3 million, including €9.3 million of UZEDY® royalties, confirming the evolution of the…
5 months ago businesswire.com
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today…
5 months ago businesswire.com
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable…
5 months ago seekingalpha.com
MedinCell S.A. (MDCLF) Discusses Long-Acting Injectable Platform, R&D Strategy, and Value Creation Approach Transcript
MedinCell S.A. (MDCLF) Discusses Long-Acting Injectable Platform, R&D Strategy, and Value Creation Approach Transcript
6 months ago businesswire.com
Medincell to Host an Online R&D Day on Tuesday, May 12, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) will host an online R&D Day, held in English, on Tuesday, May 12, 2026, from 4:00 to 5:30 pm CEST (10:00 -…
8 months ago businesswire.com
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable…
9 months ago businesswire.com
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and…
10 months ago seekingalpha.com
MedinCell S.A. (MDCLF) Q2 2026 Earnings Call Transcript
MedinCell S.A. (MDCLF) Q2 2026 Earnings Call Transcript